drugset / Trial / NCT03608501
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the overall response rate (ORR) during induction therapy with the combination of ixazomib, thalidomide and low-dose dexamethasone in specific time points.
Timeline
- Start
- 2019-09-30
- Primary completion
- 2021-06-30
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Ixazomib | Unknown | 4 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |